BIONCaRT receives approval to conduct a clinical trial with stem cells for the treatment of cartilage damage in the knee joint

BION­CaRT GmbH has received approval to con­duct a clin­i­cal phase I/IIa study from the respon­si­ble national higher fed­eral author­ity, the Paul Ehrlich Insti­tute. The aim of the study is to inves­ti­gate the safety and ini­tial indi­ca­tions of the effi­cacy of mes­enchy­mal stro­mal cells obtained from umbil­i­cal cord tis­sue for the treat­ment of car­ti­lage dam­age in the knee joint. 

read more »

Newsletter Q4/2024

Ode to the Founders This newslet­ter will be the last that I write as CEO of bm|t. After a ful­fill­ing and pro­duc­tive seven and a

read more »